Clinical Trial Update: Nivolumab in Combination With Chemotherapy for FGFR2-positive Metastatic Gastric Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating nivolumab in combination with chemotherapy for FGFR2-amplified metastatic gastric cancer with PD-L1 amplification are ongoing, status n…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: Kidney Cancer Research Bureau | Conditions: Metastatic Gastric Cancer, PD-L1 Gene Amplification | Phase 2 | Status: UNKNOWN